Objective: To systematically examine the prognostic significance of isocitrate dehydrogenase 1 (IDH1) mutations according to country region. Methods: We searched five electronic databases from inception to September 2019 for relevant studies. A meta-analysis was performed after evaluating which studies met the inclusion criteria. Thirty-seven were identified for this meta-analysis, comprising 5141 GBM patients. Results: The benefit of overall survival (OS) was the hazard ratio (HR), 0.67 (95% confidence interval [CI], 0.61–0.74). When subgroup analysis by country region, the pooled HR for the Eastern population studies was 1.15 (95% CI: 0.97–1.35) with no association between IDH1 mutation and OS of GBM, while IDH1 mutation still had a significant survival advantage in the Western population studies (HR: 0.51, 95% CI: 0.45–0.57). Conclusions: This study confirmed that IDH1 mutation is an independent prognostic factor for patients with GBM. However, a topographic relationship was observed in the results, and an association between this genetic mutation and prognosis should be explored in future studies.
Glioblastoma, isocitrate dehydrogenase 1, meta-analysis, survival, systematic review